Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety and Tolerability of GS-4528 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

NCT05840224 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05840224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05840224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety and Tolerability of GS-4528 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 11, 2023
Completion date
October 31, 2026
Enrollment
182 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor